期刊文献+

冠状动脉病变介入治疗应用替罗非班时机的探讨

下载PDF
导出
摘要 经皮冠状动脉介入治疗(PCI)是冠状动脉血运重建的有效方法,但对心肌易造成损伤,尤其是复杂冠状动脉病变的PCI治疗。PCI术相关心肌损伤与手术诱发血小板的激活与聚集有关121。血小板糖蛋白(GP)IIb/IIIa受体拮抗剂替罗非班可以抑制血小板聚集,减少PCI相关的心肌损伤,但使用时机目前学者的观点不一致。本文拟通过复杂冠状动脉病变PCI术前及术后即时应用替罗非班的对比分析,对其疗效与安全性作一评价。
出处 《浙江临床医学》 2013年第6期835-836,共2页 Zhejiang Clinical Medical Journal
  • 相关文献

参考文献8

  • 1黄超联,朱文玲,沈珠军,曾勇,姜秀春,李燕华.冠状动脉介入治疗后血清心肌酶谱升高对预后的影响[J].中华心血管病杂志,2003,31(3):189-191. 被引量:6
  • 2刘剑雄,燕纯伯.经皮冠状动脉介入术相关心肌损伤的研究现状及进展[J].心血管病学进展,2007,28(6):899-903. 被引量:4
  • 3Qiang Xu, Jian Yin, Liang-yi Si.Effecacy and safety of early versus late glycoprotein lib/Ilia inhibitors for PCI.IntJ Cardiol, 2012, 348(7): 593-600.
  • 4Stone GW, MosesJW, Ellis SG, et al.Safety and eflficacy ofsirofimus- and paclitaxel-eluting coronary stents.N Engl J Med, 2007, 356:998-1008.
  • 5Quinn MJ, Byzova TV, Qin J, et al.Integrin alphalIbbeta3 and its antagonism.Arterioscler Thromb Vasc Biol, 2003, 23:945-952.
  • 6李芳,王琳,卜军.替罗非班治疗急性冠脉综合征的临床研究[J].内科急危重症杂志,2004,10(2):72-74. 被引量:17
  • 7Talarico GP, Brancati M, Burzotta F, et al.Glycoprotein liB/IliA inhibitor to reduce postloercutaneous coronary intervention myonecrosis and improve coronary flow in diabetics:the "OPTIMIZE-IT" pilot randomized studyJ Cardiovasc Med, 2009, 10:245-251.
  • 8Rodriguez AE, Mieres J, Fernandez-Pereira C, et al.Coronary stent thrombosis in the current drug-eluting stent era:insights from the EP, ACI Ⅲ trialJ Am Coil Cardiol, 2006, 47:205-207.

二级参考文献13

  • 1FU Xiang-hua FAN Wei-ze GU Xin-shun WEI Yong-yun JIANG Yun-fa WU Wei-li LI Shi-qiang HAO Guo-zhen WEI Qing-min XUE Ling.Effect of intracoronary administration of anisodamine on slow reflow phenomenon following primary percutaneous coronary intervention in patients with acute myocardial infarction[J].Chinese Medical Journal,2007(14):1226-1231. 被引量:38
  • 2Ravkilde J,Nissen H,Mickley H, et al. Cardiac troponin T and CK-MB mass release after visually successful PTCA in stable angina pectoris. Am Heart J, 1994, 127:13-20.
  • 3Kini A, Marmur JD, Kini S, et al. Creatlne kinase-MB elevation after coronary intervention correlates with diffuse atheroeclerosis, and low-to-medium level elevation has a benign clinical course: implications for early discharge after coronary intervention. J Am Coil Cardiol, 1999,.
  • 4Kong Q, Davidson C, Meyers N, et al. Prognostic implication of creatine kinase elevation following elective coronary artery interventions.JAMA, 1997, 277:461-466.
  • 5Van de Wed F. More evidence for a beneficial effect of platelet glycoprotein b/a blockade during coronary interventiona-latest results from EPILOG and CAPYURE trials. Eur Heart J, 1996, 17:325-326.
  • 6Ohman E, Califf R, Topoi E. Cardiac troponins in acute coronary syndromes. N Engl J Med, 1997, 336:1257-1259.
  • 7The RESTPRE Investigators. Effects of platelet glycoprotein IIb/IIIa blockage with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation, 1997,96: 1445.
  • 8Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med, 1998,338:1498.
  • 9The PRISM-PLUS Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med, 1998,338:1488.
  • 10James C. Bleeding complications of glycoprotein IIb/IIIa receptor inhibitors. Am Heart J, 1999,138:S287.

共引文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部